AbbVie Inc. ABBV
At closeNov 9, 2026, 4:06 PM EST
After hours · Nov 9, 4:06 PM ET
- YTD
- +28.37%
- 1 year
- +33.83%
- Market cap
- 518.45B
- Revenue (ttm)
- 66.01B
- Profit margin
- 15.67%
- EPS (ttm)
- 5.82
- Shares out
- 1.77B
- P/E ratio
- 50.40
- Forward P/E
- 18.12
- Dividend
- 6.92 (2.40%)
- Ex-dividend date
- Jan 14, 2027
- YTD return
- +28.37%
- 1-year return
- +33.83%
- Volume
- 3.83M
- Avg volume
- 4.81M
- Open
- 293.84
- Previous close
- 291.31
- Day's range
- 289.62 – 294.57
- 52-week range
- 190.75 – 302.93
- Beta
- 0.19
- Analysts
- Buy
- Price target
- 310.65 (+5.9%)
- Earnings date
- Feb 3, 2027
5D +3.04 (+1.05%)
Key statistics
- Enterprise value
- 585.51B
- PEG ratio
- 0.59
- Price / sales
- 7.85
- Price / book
- 0.00
- Dividend yield
- 2.38%
- Payout ratio
- 117.35%
- Revenue growth
- 10.30%
- Free cash flow
- 17.69B
- Total cash
- 10.77B
- Total debt
- 81.32B
- Return on equity
- 0.00%
- Short % of float
- 0.98%
- 50-day average
- 271.95
- 200-day average
- 238.94
Analyst view
Consensus: buy
- Target (low)
- 237.00
- Target (mean)
- 310.65
- Target (high)
- 350.00
- Strong buy7
- Buy16
- Hold5
- Sell0
- Strong sell1
Next earnings
Feb 3, 2027
Expected Feb 3, 2027. Consensus EPS estimate 3.88.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 3, 2027 | Dec 30, 2026 | 3.89 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 3.73 | 3.82 | +0.09 | +2.41% |
| Jul 31, 2026 | Jun 30, 2026 | 3.61 | 3.65 | +0.04 | +1.11% |
| Apr 29, 2026 | Mar 31, 2026 | 2.59 | 2.65 | +0.06 | +2.32% |
| Feb 4, 2026 | Dec 31, 2025 | 2.65 | 2.71 | +0.06 | +2.26% |
| Oct 31, 2025 | Sep 30, 2025 | 1.77 | 1.86 | +0.09 | +5.08% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | UBS | main | Neutral | Neutral |
| Nov 2, 2026 | Leerink Partners | main | Outperform | Outperform |
| Nov 2, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Nov 2, 2026 | Guggenheim | main | Buy | Buy |
| Nov 2, 2026 | Wells Fargo | main | Overweight | Overweight |
| Nov 2, 2026 | RBC Capital | main | Outperform | Outperform |
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Website
- abbvie.com
News
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? 
Reported Sunday, Allergan Aesthetics’ HALO Interim Results Show 95.7% Of 25 Adults On GLP-1 Medications Satisfied Or Very Satisfied They Still Looked Like Themselves After HA Injectables, With 39.6-Point FACE-Q Gain 
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today 
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? 
Dividend Announcements: October 24-30, 2026 (Part 1 Of 2) 
AbbVie expands Oxford R&D facility as part of £120 million-plus investment 
AbbVie Hit a New High After Earnings. There's More Upside Left. 
Allergan Aesthetics to Present New Research on Aesthetic Care Following Medical Weight Loss and Evolving Patient Needs at ASDS 2026 
AbbVie Inc. $ABBV Position Lessened by BOCHK Asset Management Ltd 
UBS Maintains Neutral on AbbVie, Raises Price Target to $295
Your note
Sign in to keep a note on ABBV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONOGHOE NICHOLAS | Officer | Sale | Aug 13, 2026 | 74,430 |
| FREYMAN THOMAS C | Director | Stock Award(Grant) | May 7, 2026 | 135,751 |
| GONZALEZ RICHARD A | Director | Stock Gift | Mar 30, 2025 | 386,479 |
| MICHAEL ROBERT A. | Chief Executive Officer | Stock Award(Grant) | Feb 17, 2026 | 215,260 |
| RAPP EDWARD J | Director | Stock Award(Grant) | May 7, 2026 | 45,964 |
| REENTS SCOTT T. | Chief Financial Officer | Stock Award(Grant) | Feb 17, 2026 | 60,415 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.46% | 149,488,412 | 43.84B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.53% | 115,396,098 | 33.84B | Jun 29, 2026 |
| State Street Corporation | 4.67% | 82,596,748 | 24.22B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 2.74% | 48,477,996 | 14.22B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 2.71% | 47,862,796 | 14.04B | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.69% | 47,503,777 | 13.93B | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 56,090,167 | 16.45B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.59% | 45,784,614 | 13.43B | Jun 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.33% | 23,546,125 | 6.91B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.30% | 22,965,383 | 6.73B | Sep 29, 2026 |
| SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust | 1.24% | 21,857,356 | 6.41B | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Value Index Fund | 0.95% | 16,815,764 | 4.93B | Jun 29, 2026 |